Literature DB >> 9845397

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.

M P Williams1, J Sercombe, M I Hamilton, R E Pounder.   

Abstract

BACKGROUND: Rabeprazole (LY307640, E3810) is a new, potent, proton pump inhibitor. A single daily 20 mg dose significantly decreases 24-h intragastric acidity. There are no data currently available directly comparing the effect of rabeprazole on 24-h acidity with established proton pump inhibitors. AIM: To compare the effects of rabeprazole 20 mg o.m. and omeprazole 20 mg o.m. on 24-h intragastric acidity and plasma gastrin concentration in a randomized, double-blind, placebo-controlled trial, in healthy H. pylori-negative subjects.
METHODS: Twenty-four healthy male volunteers, negative for H. pylori infection by serology and 13C-urea breath test, were studied on the 1st and 8th day of dosing with either placebo, rabeprazole 20 mg or omeprazole 20 mg, once each morning, in a crossover fashion. On days 1 and 8, hourly intragastric acidity was measured by gastric aspiration for 24 h from 08.00 hours. On day 8, plasma gastrin concentrations were also measured hourly from 08.00 to 24.00 hours, then every 2 h thereafter.
RESULTS: A single dose of both rabeprazole and omeprazole significantly decreased 24-h intragastric acidity compared with placebo. The 24-h acidity on day 1 was significantly decreased for rabeprazole compared with omeprazole (331 vs. 640 mmol.h/L, P < 0.001), resulting in a significantly higher median 24-h intragastric pH and longer times at which intragastric pH was > 3 and > 4. On day 8 of dosing, the decrease in 24-h intragastric acidity was greater with rabeprazole than with omeprazole, but the difference was not statistically significant (160 vs. 218 mmol.h/L, P = 0.1). However, 24-h plasma gastrin concentration (1687 vs. 1085 pmol.h/L. P < 0.01) and percentage time that intragastric pH was > 3 (69 vs. 59%, P = 0.008) and > 4 (60 vs. 51%, P = 0.03) were significantly greater.
CONCLUSIONS: Rabeprazole 20 mg once daily has a significantly faster onset of antisecretory activity than omeprazole 20 mg once daily. After 8 days the differences in intragastric pH > 3 and > 4 holding times persisted, but there was no significant difference in 24-h acidity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845397     DOI: 10.1046/j.1365-2036.1998.00418.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  42 in total

1.  Rabeprazole: quest for the best PPI.

Authors:  Kentaro Sugano
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

2.  Early effects of oral administration of omeprazole and roxatidine on intragastric pH.

Authors:  Hiroshi Iida; Shingo Kato; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroki Endo; Kunihiro Hosono; Yasunari Sakamoto; Koji Fujita; Masato Yoneda; Tomoko Koide; Hirokazu Takahashi; Chikako Tokoro; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Kensuke Kubota; Eiji Gotoh; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

Review 3.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

4.  Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Authors:  Hank S Wang; David S Oh; Ariana Anderson; Jose Nieto; Phuong Tien; Gordon Ohning; Joseph R Pisegna
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

Review 5.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.

Authors:  Yong-Mei Hu; Qiao Mei; Xin-Hua Xu; Xiang-Peng Hu; Nai-Zhong Hu; Jian-Ming Xu
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

7.  A novel method to radiolabel gastric retentive formulations for gamma scintigraphy assessment.

Authors:  Matthew D Burke; J Scott Staton; Ann W Vickers; Erin E Peters; Mark D Coffin
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

8.  Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.

Authors:  Takashi Ando; Takeshi Ishikawa; Satoshi Kokura; Yuji Naito; Norimasa Yoshida; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

9.  Regional postprandial differences in pH within the stomach and gastroesophageal junction.

Authors:  Hrair P Simonian; Lien Vo; Siva Doma; Robert S Fisher; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 10.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.